Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 27864418
Jang JE, et al. (2017) AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells. Clin Cancer Res 23, 2781-2794 27864418
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T183-p - AMPKA1 (human)
Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 iso2 (human): T198‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia, acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b), acute myeloblastic leukemia, with granulocytic maturation (M2)
Relevant cell lines - cell types - tissues:  Kasumi-1 (myeloid), KG-1 (myeloid), KG-1a (myeloid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
JQ1 increase primary AML cells
JQ1 AMPKA1 (human) increase AMPK siRNA decrease in KGF1 and KG1a cells
compound_C JQ1 AMPKA1 (human) decrease

S2448-p - mTOR (human)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia, acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b), acute myeloblastic leukemia, with granulocytic maturation (M2)
Relevant cell lines - cell types - tissues:  Kasumi-1 (myeloid), KG-1 (myeloid), KG-1a (myeloid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
JQ1 decrease primary AML cells

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia, acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b), acute myeloblastic leukemia, with granulocytic maturation (M2)
Relevant cell lines - cell types - tissues:  Kasumi-1 (myeloid), KG-1 (myeloid), KG-1a (myeloid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
JQ1 decrease primary AML cells

S556-p - ULK1 (human)
Modsite: GLGCRLHsAPNLsDL SwissProt Entrez-Gene
Orthologous residues
ULK1 (human): S556‑p, ULK1 (mouse): S555‑p, ULK1 (rat): S555‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia, acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b), acute myeloblastic leukemia, with granulocytic maturation (M2)
Relevant cell lines - cell types - tissues:  Kasumi-1 (myeloid), KG-1 (myeloid), KG-1a (myeloid)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
JQ1 no change compared to control primary AML cells
JQ1 AMPKA1 (human) increase AMPK siRNA decrease in KGF1 and KG1a cells
compound_C JQ1 AMPKA1 (human) decrease